위식도 역류 질환의 진단과 치료에 관한 서울 진료지침 2020

키워드

참고문헌 (136)

1. Vakil N, "The Montreal definition and classification of gastroesophageal reflux disease : a global evidence-based consensus", Am J Gastroenterol, 101, pp.1900~1920 (2006)
2. Richter JE, "Presentation and epidemiology of gastroesophageal reflux disease", Gastroenterology, 154, pp.267~276 (2018)
3. Pace F, "Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed)", Am J Gastroenterol, 99, pp.946~949 (2004)
4. Katzka DA, "Phenotypes of gastroesophageal reflux disease : where rome, Lyon, and Montreal meet", Clin Gastroenterol Hepatol, 18, pp.767~776 (2020)
5. Aziz Q, "Functional esophageal disorders", Gastroenterology, 150, pp.1368~1379 (2016)
6. Gyawali CP, "Modern diagnosis of GERD : the Lyon consensus", Gut, 67, pp.1351~1362 (2018)
7. Hye-Kyung Jung, "2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease", Journal of Neurogastroenterology and Motility (JNM), 27(4), pp.453~481 (2021), 대한소화기 기능성질환∙운동학회[DOI]
8. "Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach" (2013)[URL]
9. Andrews J, "GRADE guidelines : 14. Going from evidence to recommendations : the significance and presentation of recommendations", J Clin Epidemiol, 66, pp.719~725 (2013)
10. Ronkainen J, "High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population:a Kalixanda study report", Scand J Gastroenterol, 40, pp.275~285 (2005)
11. Savarino E, "Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease : study using combined impedance-pH offtherapy", Am J Gastroenterol, 105, pp.1053~1061 (2010)
12. Savarino E, "NERD : an umbrella term including heterogeneous subpopulations", Nat Rev Gastroenterol Hepatol, 10, pp.371~380 (2013)
13. Sifrim D, "Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors", Gut, 61, pp.1340~1354 (2012)
14. Iwakiri K, "Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015", J Gastroenterol, 51, pp.751~767 (2016)
15. Hunt R, "World gastroenterology organisation global guidelines : GERD global perspective on gastroesophageal reflux disease", J Clin Gastroenterol, 51, pp.467~478 (2017)
16. Fock KM, "Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus", Gut, 65, pp.1402~1415 (2016)
17. Niu XP, "Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease", World J Gastroenterol, 19, pp.3124~3129 (2013)
18. Bytzer P, "Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients", Aliment Pharmacol Ther, 36, pp.635~643 (2012)
19. Carlsson R, "Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD study group", Eur J Gastroenterol Hepatol, 10, pp.119~124 (1998)
20. Bardhan KD, "The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease", Aliment Pharmacol Ther, 9(Suppl 1), pp.15~25 (1995)
21. Fass R, "Symptom assessment tools for gastroesophageal reflux disease (GERD) treatment", J Clin Gastroenterol, 41, pp.437~444 (2007)
22. Miwa H, "Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease : a multicenter study from Japan", Aliment Pharmacol Ther, 26, pp.69~77 (2007)
23. Furuta T, "Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the acid-related symptom research group in Japan", J Gastroenterol, 46, pp.1273~1283 (2011)
24. Lee ES, "Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease", Aliment Pharmacol Ther, 30, pp.154~164 (2009)
25. Amarasiri LD, "Prevalence of gastro-oesophageal reflux disease symptoms and reflux-associated respiratory symptoms in asthma", BMC Pulm Med, 10, pp.49~ (2010)
26. Zerbib F, "Esophageal pH-impedance monitoring and symptom analysis in GERD : a study in patients offand on therapy", Am J Gastroenterol, 101, pp.1956~1963 (2006)
27. Sansone RA, "Hoarseness : a sign of self-induced vomiting?", Innov Clin Neurosci, 9, pp.37~41 (2012)
28. 박창규, "Prevalence of Gastrointestinal Diseases and Treatment Status in Noncardiac Chest Pain Patients", Korean Circulation Journal, 45(6), pp.469~472 (2015), 대한심장학회[DOI]
29. 민양원, "Prevalence of Extraesophageal Symptoms in Patients With Gastroesophageal Reflux Disease: A Multicenter Questionnaire-based Study in Korea", Journal of Neurogastroenterology and Motility (JNM), 20(1), pp.87~93 (2014), 대한소화기 기능성질환∙운동학회
30. 정혜경, "Epidemiology of Gastroesophageal Reflux Disease in Asia: A Systematic Review", Journal of Neurogastroenterology and Motility (JNM), 17(1), pp.14~27 (2011), 대한소화기 기능성질환∙운동학회
31. Bolier EA, "Systematic review : questionnaires for assessment of gastroesophageal reflux disease", Dis Esophagus, 28, pp.105~120 (2015)
32. Jones R, "Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care", Aliment Pharmacol Ther, 30, pp.1030~1038 (2009)
33. Shaw MJ, "Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease", Am J Gastroenterol, 96, pp.52~57 (2001)
34. Roman S, "Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux", Neurogastroenterol Motil, 27, pp.1667~1674 (2015)
35. Weijenborg PW, "Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis", Am J Physiol Gastrointest Liver Physiol, 307, pp.G323~G329 (2014)
36. Codipilly DC, "The effect of endoscopic surveillance in patients with Barrett’s esophagus : a systematic review and meta-analysis", Gastroenterology, 154, pp.2068~2086.e5 (2018)
37. Corley DA, "Surveillance and survival in Barrett’s adenocarcinomas : a population-based study", Gastroenterology, 122, pp.633~640 (2002)
38. El-Serag HB, "Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus", Gut, 65, pp.1252~1260 (2016)
39. Royston C, "The evolution and outcome of surveillance of Barrett’s oesophagus over four decades in a UK district general hospital", Eur J Gastroenterol Hepatol, 28, pp.1365~1373 (2016)
40. Verbeek RE, "Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma : a population-based cohort study", Am J Gastroenterol, 109, pp.1215~1222 (2014)
41. Chandrasekar VT, "Significantly lower annual rates of neoplastic progression in short-compared to long-segment non-dysplastic Barrett’s esophagus : a systematic review and metaanalysis", Endoscopy, 51, pp.665~672 (2019)
42. Katz PO, "Guidelines for the diagnosis and management of gastroesophageal reflux disease", Am J Gastroenterol, 108, pp.308~328 (2013)
43. Abdallah J, "Most patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy also have functional esophageal disorders", Clin Gastroenterol Hepatol, 17, pp.1073~1080.e1 (2019)[DOI]
44. Park EY, "The value of early wireless esophageal pH monitoring in diagnosing functional heartburn in refractory gastroesophageal reflux disease", Dig Dis Sci, 58, pp.2933~2939 (2013)
45. Kohata Y, "Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring", J Gastroenterol Hepatol, 27(Suppl 3), pp.58~62 (2012)
46. Mainie I, "Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring", Gut, 55, pp.1398~1402 (2006)
47. Patel A, "Prevalence, characteristics, and treatment outcomes of reflux hypersensitivity detected on pH-impedance monitoring", Neurogastroenterol Motil, 28, pp.1382~1390 (2016)
48. Kim SY, "Normal acid exposure time in esophageal pH monitoring in Asian and Western populations : A systematic review and meta-analysis", Neurogastroenterol Motil, 33, pp.e14029~ (2021)
49. Aanen MC, "Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association", J Clin Gastroenterol, 42, pp.441~447 (2008)
50. Kushnir VM, "Abnormal GERD parameters on ambulatory pH monitoring predict therapeutic success in noncardiac chest pain", Am J Gastroenterol, 105, pp.1032~1038 (2010)
51. Galindo G, "Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy", Dis Esophagus, 26, pp.443~450 (2013)
52. Gyawali CP, "Ineffective esophageal motility : concepts, future directions, and conclusions from the Stanford 2018 symposium", Neurogastroenterol Motil, 31, pp.e13584~ (2019)
53. Shaker A, "Multiple rapid swallow responses during esophageal high-resolution manometry reflect esophageal body peristaltic reserve", Am J Gastroenterol, 108, pp.1706~1712 (2013)
54. Tolone S, "Esophagogastric junction contractility for clinical assessment in patients with GERD : a real added value?", Neurogastroenterol Motil, 27, pp.1423~1431 (2015)
55. Ho SC, "Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease", Dig Dis Sci, 47, pp.652~656 (2002)
56. Rengarajan A, "Esophagogastric junction and esophageal body contraction metrics on high-resolution manometry predict esophageal acid burden", Neurogastroenterol Motil, 30, pp.e13267~ (2018)
57. Reddy CA, "Impact of symptom burden and health-related quality of life (HRQOL) on esophageal motor diagnoses", Neurogastroenterol Motil, 29, pp.e12970~ (2017)
58. Roman S, "Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease : update of the porto consensus and recommendations from an international consensus group", Neurogastroenterol Motil, 29, pp.1~15 (2017)
59. Vaezi MF, "Assessing old and new diagnostic tests for gastroesophageal reflux disease", Gastroenterology, 154, pp.289~301 (2018)
60. Matteo Ghisa, "The Lyon Consensus: Does It Differ From the Previous Ones?", Journal of Neurogastroenterology and Motility (JNM), 26(3), pp.311~321 (2020), 대한소화기 기능성질환∙운동학회[DOI]
61. Farré R, "Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique", Gut, 60, pp.885~892 (2011)
62. Ates F, "Mucosal impedance discriminates GERD from non-GERD conditions", Gastroenterology, 148, pp.334~343 (2015)
63. Frazzoni M, "Analyses of the postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease", Clin Gastroenterol Hepatol, 14, pp.40~46 (2016)
64. El-Serag H, "The association between obesity and GERD : a review of the epidemiological evidence", Dig Dis Sci, 53, pp.2307~2312 (2008)
65. Singh M, "Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial", Obesity (Silver Spring), 21, pp.284~290 (2013)
66. Tack J, "Pathophysiology of gastroesophageal reflux disease", Gastroenterology, 154, pp.277~288 (2018)
67. Jacobson BC, "Body-mass index and symptoms of gastroesophageal reflux in women", N Engl J Med, 354, pp.2340~2348 (2006)
68. Eusebi LH, "Global prevalence of, and risk factors fOR gastro-oesophageal reflux symptoms : a meta-analysis", Gut, 67, pp.430~440 (2018)
69. de Bortoli N, "Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease : a comparative study", Dis Esophagus, 29, pp.197~204 (2016)
70. Ness-Jensen E, "Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study : the HUNT study", Am J Gastroenterol, 108, pp.376~382 (2013)
71. Mathus-Vliegen EM, "Gastro-oesophageal reflux in obese subjects : influence of overweight, weight loss and chronic gastric balloon distension", Scand J Gastroenterol, 37, pp.1246~1252 (2002)
72. Fraser-Moodie CA, "Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight", Scand J Gastroenterol, 34, pp.337~340 (1999)
73. Kjellin A, "Gastroesophageal reflux in obese patients is not reduced by weight reduction", Scand J Gastroenterol, 31, pp.1047~1051 (1996)
74. Chiba N, "Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease : a meta-analysis", Gastroenterology, 112, pp.1798~1810 (1997)
75. Sigterman KE, "Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease", Cochrane Database Syst Rev, 2013, pp.CD002095~ (2013)
76. Kinoshita Y, "Efficacy of twice-daily rabeprazole for reflux esophagitis patients, refractory to standard once-daily administration of PPI : the Japan-based TWICE study", Am J Gastroenterol, 107, pp.522~530 (2012)
77. Gralnek IM, "Esomeprazole versus other proton pump inhibitors in erosive esophagitis : a meta-analysis of randomized clinical trials", Clin Gastroenterol Hepatol, 4, pp.1452~1458 (2006)
78. Bayerdörffer E, "Randomized, multicenter study : on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease", BMC Gastroenterol, 16, pp.48~ (2016)
79. van der Velden AW, "Pharmacological dependency in chronic treatment of gastroesophageal reflux disease : a randomized controlled clinical trial", Digestion, 81, pp.43~52 (2010)
80. Szucs T, "Cost analysis of longterm treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland", Value Health, 12, pp.273~281 (2009)
81. Morgan DG, "Maintenance treatment of gastroesophageal reflux disease : an evaluation of continuous and on-demand therapy with rabeprazole 20 mg", Can J Gastroenterol, 21, pp.820~826 (2007)
82. Sjöstedt S, "Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis", Aliment Pharmacol Ther, 22, pp.183~191 (2005)
83. Norman Hansen A, "A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease", Int J Clin Pract, 59, pp.665~671 (2005)
84. Janssen W, "Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease : once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term", Curr Ther Res Clin Exp, 66, pp.345~363 (2005)
85. Achem SR, "Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux", Dig Dis Sci, 42, pp.2138~2145 (1997)
86. Bautista J, "The effect of an empirical trial ofhigh-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial", Aliment Pharmacol Ther, 19, pp.1123~1130 (2004)
87. Dickman R, "The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain : a randomized, double-blind, placebo-controlled, crossover trial", Aliment Pharmacol Ther, 22, pp.547~555 (2005)
88. Fass R, "The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain", Gastroenterology, 115, pp.42~49 (1998)
89. Flook NW, "Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care : a randomized, double-blind, placebo-controlled trial", Am J Gastroenterol, 108, pp.56~64 (2013)
90. Pandak WM, "Short course of omeprazole : a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring", J Clin Gastroenterol, 35, pp.307~314 (2002)
91. Xia HH, "Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with noncardiac chest pain", Aliment Pharmacol Ther, 17, pp.369~377 (2003)
92. Shaheen NJ, "ACG clinical guideline : diagnosis and management of barrett’s esophagus", Am J Gastroenterol, 111, pp.30~50 (2016)
93. de Jonge PJ, "Risk factors for the development of esophageal adenocarcinoma in Barrett’s esophagus", Am J Gastroenterol, 101, pp.1421~1429 (2006)
94. Masclee GM, "NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus : a population-based case-control study", BMJ Open, 5, pp.e006640~ (2015)
95. Tan MC, "Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett’s oesophagus : a nested case-control study in US male veterans", Aliment Pharmacol Ther, 48, pp.469~477 (2018)
96. Hillman LC, "Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus", Med J Aust, 180, pp.387~391 (2004)
97. Nguyen DM, "Medication usage and the risk of neoplasia in patients with Barrett’s esophagus", Clin Gastroenterol Hepatol, 7, pp.1299~1304 (2009)
98. Jung KW, "Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study", Am J Gastroenterol, 106, pp.1447~1455 (2011)
99. Kastelein F, "Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus", Clin Gastroenterol Hepatol, 11, pp.382~388 (2013)
100. Loo VG, "Host and pathogen factors for Clostridium difficile infection and colonization", N Engl J Med, 365, pp.1693~1703 (2011)
101. Moayyedi P, "Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin", Gastroenterology, 157, pp.682~691.e2 (2019)
102. Beil W, "Mechanism of gastric antisecretory effect of SCH 28080", Br J Pharmacol, 88, pp.19~23 (1986)
103. Tadayuki Oshima, "Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases", Journal of Neurogastroenterology and Motility (JNM), 24(3), pp.334~344 (2018), 대한소화기 기능성질환∙운동학회[DOI]
104. Xiao Y, "Phase III, randomized, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis", Gut, 69, pp.224~230 (2020)
105. Ashida K, "Randomized clinical trial : vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis", Aliment Pharmacol Ther, 43, pp.240~251 (2016)
106. Ashida K, "Randomized clinical trial: adose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis", Aliment Pharmacol Ther, 42, pp.685~695 (2015)
107. Miyazaki H, "Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease : a systematic review", J Gastroenterol Hepatol, 34, pp.1316~1328 (2019)
108. Han S, "Randomized clinical trial:safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 50, pp.751~759 (2019)
109. Lee KJ, "Randomized phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.864~872 (2019)
110. Peghini PL, "Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors", Am J Gastroenterol, 93, pp.763~767 (1998)
111. Wang Y, "Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough", Cochrane Database Syst Rev, pp.CD004275~ (2009)
112. Fackler WK, "Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough", Gastroenterology, 122, pp.625~632 (2002)
113. Miwa H, "Randomized clinical trial:efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study", Aliment Pharmacol Ther, 33, pp.323~332 (2011)
114. Miyamoto M, "Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy", Intern Med, 49, pp.1469~1476 (2010)
115. Liu Q, "Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease : a systematic review", World J Gastroenterol, 19, pp.9111~9118 (2013)
116. Grossi L, "Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients : a 48-h manometric study", Neurogastroenterol Motil, 20, pp.760~766 (2008)
117. Koek GH, "Effect of the GABA(B) agonist baclofen in patients with symptoms and duodenogastro-oesophageal reflux refractory to proton pump inhibitors", Gut, 52, pp.1397~1402 (2003)
118. van Herwaarden MA, "The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease", Aliment Pharmacol Ther, 16, pp.1655~1662 (2002)
119. Ciccaglione AF, "Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease", Gut, 52, pp.464~470 (2003)
120. Cossentino MJ, "Randomized clinical trial : the effect of baclofen in patients with gastro-oesophageal reflux--a randomized prospective study", Aliment Pharmacol Ther, 35, pp.1036~1044 (2012)
121. Cange L, "Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease", Aliment Pharmacol Ther, 16, pp.869~873 (2002)
122. Li S, "The effects of baclofen for the treatment of gastroesophageal reflux disease : a meta-analysis of randomized controlled trials", Gastroenterol Res Pract, 2014, pp.307805~ (2014)
123. Mandel KG, "Review article : alginate-raft formulations in the treatment of heartburn and acid reflux", Aliment Pharmacol Ther, 14, pp.669~690 (2000)
124. Kahrilas PJ, "The acid pocket : a target for treatment in reflux disease?", Am J Gastroenterol, 108, pp.1058~1064 (2013)
125. Kwiatek MA, "An alginate-antacid formulation (gaviscon double action liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients", Aliment Pharmacol Ther, 34, pp.59~66 (2011)
126. Wilkinson J, "Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (gaviscon double action) chewable tablets in patients with gastro-oesophageal reflux disease", Eur J Gastroenterol Hepatol, 31, pp.86~93 (2019)
127. Lai IR, "Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease", World J Gastroenterol, 12, pp.747~754 (2006)
128. Tran T, "Meta-analysis : the efficacy of over-the-counter gastro-oesophageal reflux disease therapies", Aliment Pharmacol Ther, 25, pp.143~153 (2007)
129. Chiu CT, "Randomized clinical trial:sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease", Aliment Pharmacol Ther, 38, pp.1054~1064 (2013)
130. Fass R, "Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease", Surg Endosc, 31, pp.4865~4882 (2017)
131. Noar M, "Long-term maintenance effect of radiofrequency energy delivery for refractory GERD : a decade later", Surg Endosc, 28, pp.2323~2333 (2014)
132. Lipka S, "No evidence for efficacy of radio-frequency ablation for treatment of gastroesophageal reflux disease : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 13, pp.1058~1067.e1 (2015)
133. Anvari M, "A randomized controlled trial of laparoscopic nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes", Surg Endosc, 25, pp.2547~2554 (2011)
134. Emken BG, "Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10years", Scand J Gastroenterol, 52, pp.11~17 (2017)
135. Mahon D, "Randomized clinical trial of laparoscopic nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux", Br J Surg, 92, pp.695~699 (2005)
136. Susan Park, "Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea", Journal of Neurogastroenterology and Motility (JNM), 26(2), pp.215~223 (2020), 대한소화기 기능성질환∙운동학회[DOI]

관련 논문AI추천